Kalaris Therapeutics, Inc. KLRS
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Kalaris Therapeutics, Inc. (KLRS) is a healthcare company listed in the US with a market value of about $37M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -59%.
About Kalaris Therapeutics
Kalaris Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. It was profitable in 0 of the last 7 years in our data. Its share count rose by 358% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $165000 |
| Net income | -$43M | -$69M | -$190M | -$169M | -$172M | -$70M | -$24M |
| Free cash flow | -$39M | — | — | — | -$106M | -$61M | -$20M |
| EPS (diluted) | $-2.85 | $-51.77 | $-42.09 | $-50.60 | $-63.02 | $-59.57 | $-426.42 |
| Net margin | — | — | — | — | — | — | -14447.9% |
| ROIC | -57.5% | — | — | -65.8% | -52.5% | -15.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Kalaris Therapeutics pay a dividend?
Not currently.
Is Kalaris Therapeutics a good stock to buy?
We do not give buy or sell advice. Kalaris Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.